Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Operating Expenses of $7.0 million for Q4 2025, up 2454.32% on a YoY basis from $275613.0 in Q4 2024, and up 281.73% quarter-over-quarter from $1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Operating Expenses for 2 years, with the latest figure at $7.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 2454.32% year-over-year to $7.0 million; the trailing twelve-month figure through Dec 2025 stood at $11.9 million (up 834.25% YoY), and the FY2025 full-year result was $11.9 million, up 834.25% from the prior year.
  • Operating Expenses for Q4 2025 stood at $7.0 million, up from $1.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $7.0 million in Q4 2025, with the low at $271726.0 in Q1 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 526.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 788.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 455.70 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 19.40 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 621.10 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 478.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 441.19 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 475.11 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 96.91 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 7.04 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 7.04 Mn
Sep 30, 2025 1.84 Mn
Jun 30, 2025 2.66 Mn
Mar 31, 2025 364,368.00
Dec 31, 2024 275,613.00
Sep 30, 2024 299,999.00
Jun 30, 2024 427,757.00
Mar 31, 2024 271,726.00